Equibles does not estimate personal net worth.
Get an email with a short summary when Cardiff Oncology, Inc. publishes a filing, an earnings call transcript or a press release.
Get CRDF alertsMark Erlander is recorded as CEO at Cardiff Oncology, Inc. (CRDF). The newest filing on record that lists Mark Erlander as CEO at Cardiff Oncology, Inc. (CRDF) is dated April 23, 2026. Cardiff Oncology, Inc. reported in an 8-K filed April 2, 2026 that Mark Erlander resigned as director, effective March 27, 2026. The proxy statement of Cardiff Oncology, Inc. reports total compensation of $3,023,344 for Mark Erlander in fiscal 2025, including a base salary of $635,000. Disclosed compensation is on record for 8 fiscal years. Mark Erlander has spoken on 5 earnings calls across 1 company, most recently for Cardiff Oncology, Inc. on February 27, 2025. Cardiff Oncology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Cardiff Oncology, Inc. includes Mani Mohindru (CEO), Mani Mohindru, Ph.D. (CEO), Mark Erlander, Ph.D. (CEO) and 7 others.
“On March 27, 2026, Dr. Erlander resigned as a director of the Company.”
“Thank you, Kiki, and good afternoon, everyone, and thank you for joining our business update conference call. The fourth quarter of 2024 was significant for Cardiff Oncology.”
“Thank you, Kiki, and good afternoon, everyone, and thank you for joining our business update conference call for the second quarter of 2024. These are certainly energizing times at Cardiff Oncology as we activate sites and enroll patients in our CRDF-004 trial in RAS-mutated metastatic colorectal cancer, or mCRC.”
“Well, thank you, Kiki, and good afternoon, everyone, and thank you for joining our conference call for the first quarter of 2024 business update.”
“We have some very important new clinical data to share on the call today, which we think is highly relevant to our current first-line metastatic colorectal cancer program.”
“And thank you for joining our third-quarter 2023 financial results and corporate update conference call. As you can see on slide 3, this past quarter was transformational for Cardiff Oncology.”
Start not stated–present
Last confirmed April 23, 2026
2020-06-18–2026-03-27
Biotechnology · Healthcare
CEO
2020-06-18–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Cardiff Oncology, Inc. (CRDF) | CEO | $635,000 | $3,023,344 |
| 2024 | Cardiff Oncology, Inc. (CRDF) | CEO | $610,584 | $2,401,376 |
| 2023 | Cardiff Oncology, Inc. (CRDF) | CEO | $594,400 | $1,547,772 |
| 2022 | Cardiff Oncology, Inc. (CRDF) | CEO | $570,600 | $1,590,347 |
| 2021 | Cardiff Oncology, Inc. (CRDF) | CEO | $532,716 | $3,635,198 |
| 2020 | Cardiff Oncology, Inc. (CRDF) | CEO | $444,764 | $1,150,703 |
| 2019 | Cardiff Oncology, Inc. (CRDF) | CSO | $398,729 | $852,951 |
| 2018 | Cardiff Oncology, Inc. (CRDF) | CSO | $387,155 | $908,524 |
